“The present problem has uncovered some structural weaknesses from the EU’s medicines source chain and a higher dependence on non-EU nations for active pharmaceutical ingredients,” Kyriakides reported. She advisable that offer chain issues be dealt with in an EU pharmaceutical technique expected to generally be released by the end of the 12 m